Jump to main content
Jump to site search

Issue 7, 2013
Previous Article Next Article

A critical assessment of modeling safety-related drug attrition

Author affiliations

Abstract

This paper challenges the general desire to find simple rules and guidelines to reduce attrition due to toxicity and clinical safety. We present an analysis of 150 AstraZeneca development compounds and evaluate some of the published guidelines and their ability to identify compounds with safety liabilities. Interestingly, none of the current guidelines were able to discriminate compounds that successfully reached Phase II. The analysis was extended to recently approved drugs (2009–2011) and we found that a large portion did not comply and would never have reached patients if such guidelines had been applied at an early stage.

Graphical abstract: A critical assessment of modeling safety-related drug attrition

Back to tab navigation

Publication details

The article was received on 04 Mar 2013, accepted on 15 Apr 2013 and first published on 16 Apr 2013


Article type: Review Article
DOI: 10.1039/C3MD00072A
Med. Chem. Commun., 2013,4, 1058-1065

  •   Request permissions

    A critical assessment of modeling safety-related drug attrition

    D. Muthas, S. Boyer and C. Hasselgren, Med. Chem. Commun., 2013, 4, 1058
    DOI: 10.1039/C3MD00072A

Search articles by author

Spotlight

Advertisements